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Assessment of Bidirectional Relationships
Between Physical Activity and Depression Among Adults
A 2-Sample Mendelian Randomization Study
Karmel W. Choi, PhD; Chia-Yen Chen, PhD; Murray B. Stein, MD, MPH; Yann C. Klimentidis, PhD;
Min-Jung Wang, MSc; Karestan C. Koenen, PhD; Jordan W. Smoller, MD, ScD; for the Major Depressive Disorder
Working Group of the Psychiatric Genomics Consortium
IMPORTANCE Increasing evidence shows that physical activity is associated with reduced risk
for depression, pointing to a potential modifiable target for prevention. However, the
causality and direction of this association are not clear; physical activity may protect against
depression, and/or depression may result in decreased physical activity.
OBJECTIVE To examine bidirectional relationships between physical activity and depression
using a genetically informed method for assessing potential causal inference.
DESIGN, SETTING, AND PARTICIPANTS This 2-sample mendelian randomization (MR) used
independent top genetic variants associated with 2 physical activity phenotypes—
self-reported (n = 377 234) and objective accelerometer-based (n = 91 084)—and with major
depressive disorder (MDD) (n = 143 265) as genetic instruments from the largest available,
nonoverlapping genome-wide association studies (GWAS). GWAS were previously conducted
in diverse observational cohorts, including the UK Biobank (for physical activity) and
participating studies in the Psychiatric Genomics Consortium (for MDD) among adults of
European ancestry. Mendelian randomization estimates from each genetic instrument
were combined using inverse variance weighted meta-analysis, with alternate methods
(eg, weighted median, MR Egger, MR–Pleiotropy Residual Sum and Outlier [PRESSO]) and
multiple sensitivity analyses to assess horizontal pleiotropy and remove outliers. Data were
analyzed from May 10 through July 31, 2018.
MAIN OUTCOMES AND MEASURES MDD and physical activity.
RESULTS GWAS summary data were available for a combined sample size of 611 583 adult
participants. Mendelian randomization evidence suggested a protective relationship between
accelerometer-based activity and MDD (odds ratio [OR], 0.74 for MDD per 1-SD increase in
mean acceleration; 95% CI, 0.59-0.92; P = .006). In contrast, there was no statistically
significant relationship between MDD and accelerometer-based activity (β = −0.08 in mean
acceleration per MDD vs control status; 95% CI, −0.47 to 0.32; P = .70). Furthermore, there
was no significant relationship between self-reported activity and MDD (OR, 1.28 for MDD
per 1-SD increase in metabolic-equivalent minutes of reported moderate-to-vigorous activity;
95% CI, 0.57-3.37; P = .48), or between MDD and self-reported activity (β = 0.02 per MDD
in standardized metabolic-equivalent minutes of reported moderate-to-vigorous activity
per MDD vs control status; 95% CI, −0.008 to 0.05; P = .15).
CONCLUSIONS AND RELEVANCE Using genetic instruments identified from large-scale GWAS,
robust evidence supports a protective relationship between objectively assessed—but not
self-reported—physical activity and the risk for MDD. Findings point to the importance of
objective measurement of physical activity in epidemiologic studies of mental health and
support the hypothesis that enhancing physical activity may be an effective prevention
strategy for depression.
JAMA Psychiatry. 2019;76(4):399-408. doi:10.1001/jamapsychiatry.2018.4175
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D epression is a common psychiatric condition that rep-resents a leading cause of disability worldwide.1 De-spite this, efforts to prevent depression have been chal-
lenging, with few established protective factors, particularly
modifiable targets for prevention. One promising target is
physical activity, defined broadly as musculoskeletal move-
ment resulting in energy expenditure.2 The relationship be-
tween physical activity and depression has received much at-
tention in recent years. For example, meta-analytic data from
randomized clinical trials3 have suggested that physical ac-
tivity is linked to reduced depressive symptoms in at-risk
populations, and prospective studies4,5 have demonstrated as-
sociations between higher levels of physical activity and de-
creased risk for later depression.
Although such findings point to a potential protective role
ofphysicalactivityfordepression,severalquestionsremain.First,
does physical activity causally influence risk for depression—or
is this better explained by reverse causation? Some studies6,7
show that depression may also lead to reduced physical activ-
ity, but few studies have simultaneously tested both directional
relationships. Second, does measurement of physical activity
matter? Literature to date has relied mostly on self-reported mea-
sures of activity,5 which may be subject to confounding by par-
ticipant mood, memory inaccuracy, and social desirability bias.8
Third, does the relationship between physical activity and de-
pression persist when potential confounding is minimized? Al-
though randomized clinical trials minimize confounding from
unaccounted variables by design, they are intensive to conduct
andhavebeenofrelativelylimitedsize,withameanoffewerthan
60 participants per trial.3,9,10 More critically, randomized clini-
cal trials have focused on treating symptoms in depressed indi-
viduals rather than testing preventive effects of physical activ-
ity on depression, which has population-wide implications but
requires large samples unselected for depression. The most con-
vincing evidence to date that physical activity is associated with
a reduced risk for depression comes from meta-analyses of pro-
spective studies,5 which are high quality yet still limited by the
breadth of behavioral, social, and genetic confounders that can-
not be fully ruled out in observational designs.
Mendelian randomization (MR) is an alternative method for
potential causal inference that treats genetic variation as a natu-
ral experiment in which individuals are essentially assigned to
highervslowermeanlevelsofanongeneticexposureduringtheir
lifetime.11 Because genetic variants are considered to be allocated
randomly before birth, they are relatively independent of envi-
ronmental factors and established well before onset of disease,
thereby minimizing issues of residual confounding and reverse
causation that limit typical observational studies. If an exposure
such as physical activity causally influences an outcome such as
depression, then a variant that affects physical activity should
beexpectedtoinfluencedepressiontoaproportionaldegree,pro-
vided no separate pathway exists by which this variant can affect
depression, a phenomenon known as horizontal pleiotropy. Un-
der these conditions, variants strongly associated with an expo-
sure of interest may serve as proxies, or instruments, for estimat-
ing potential causal relationship with an outcome (Figure 1). In
a 2-sample MR design, instruments can be extracted from sum-
mary statistics of large-scale, nonoverlapping genome-wide as-
sociation studies (GWAS), which have recently become available
for physical activity12 and major depressive disorder (MDD).13
Herein, we apply bidirectional MR to assess the potential causal
relationship of physical activity with the risk for depression, and
vice versa. Furthermore, we examine genetic instruments for
physical activity assessed subjectively via self-report and objec-
tively using wearable accelerometers.
Methods
This study relied on deidentified summary-level data that have
been made publically available; ethical approval had been ob-
tained in all original studies. Summary data were available for
a combined sample of 611 583 adult participants, with corre-
sponding GWAS sample sizes detailed below. Data were ana-
lyzed for this study from May 10 through July 31, 2018.
Data Sources and Instruments
Physical Activity
We drew on summary statistics from a recent GWAS of physical
activity conducted among UK Biobank Study participants.12 This
GWAS examined the following 2 continuous physical activity
phenotypes: (1) self-reported moderate-to-vigorous physical
activity (in standardized units of inverse-normalized metabolic-
equivalent minutes per week) and (2) objective accelerometer-
based activity, specifically overall mean acceleration (in milli-
gravities across at least 72 hours of wrist-worn accelerometer
wear). The GWAS for self-reported activity (n = 377 234) identi-
fied 9 independent genome-wide significant single-nucleotide
polymorphisms (SNPs), although SNP-based heritability was
modest at approximately 5%.12 The GWAS for accelerometer-
basedactivity(n = 91 084)identifiedonly2independentgenome-
wide significant SNPs, although SNP-based heritability was
estimated much higher at 14%. These heritability estimates sug-
gest that SNPs beyond those currently identified as genome-wide
significant may contribute to variation in physical activity. Given
this, we used the following 2 sets of genetic instruments: (1) only
SNPs previously reported as genome-wide significant and (2) top
SNPsmeetingamorerelaxedthreshold(P < 1×10−7).Thismethod
of relaxing the statistical threshold for genetic instruments has
been used in psychiatric MR research when few significant SNPs
are available.14,15 When the more relaxed threshold was used, we
clumped SNPs for independence (ie, when SNPs were correlated
at r2 > 0.001, only 1 representative SNP was retained) based on
Key Points
Question Does physical activity have a potential causal role
in reducing risk for depression?
Findings In this 2-sample mendelian randomization study using
genetic instruments from large-scale genome-wide association
studies to support potential causal inference, higher levels of
physical activity (indexed by objective accelerometer data) were
linked to reduced odds for major depression.
Meaning Findings strengthen empirical support for physical
activity as an effective prevention strategy for depression.
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European ancestry reference data from the 1000 Genomes Proj-
ect. Where SNPs for the exposure phenotype were not available
inthesummarystatisticsoftheoutcomephenotype,wereplaced
themwithoverlappingproxySNPsinhigh-linkagedisequilibrium
(r2 > 0.80) identified using the LDproxy search on the online plat-
form LDlink (https://ldlink.nci.nih.gov/). Resulting lists of
instrument SNPs for each phenotype are given in eTables 1 to 4
in the Supplement.
Depression
We drew on summary statistics from the largest and most re-
cent GWAS for MDD, defined as a lifetime diagnosis of major
depression based primarily on structured assessments by
trained interviewers, clinician-administered checklists, or
medical record review.13 Overall, this case-control GWAS iden-
tified 44 independent genome-wide significant SNPs for MDD.
For the MR analysis, we used meta-analytic results for MDD
that left out UK Biobank samples, because the physical activ-
ity GWAS was also conducted in the UK Biobank, and without
23andMe samples owing to general access constraints. This
elimination resulted in a GWAS meta-analytic subsample of
143 265. As instruments, we used independent clumped SNPs
meeting a relaxed threshold (P < 1 × 10−6) to account for the
reduced meta-analytic subsample, with similar procedures for
identifying proxy SNPs as needed. The resulting list of instru-
ment SNPs is found in eTable 5 in the Supplement.
Statistical Analysis
MendelianrandomizationanalyseswereconductedintheRcom-
puting environment using the TwoSampleMR package (R Proj-
ect for Statistical Computing). This package harmonizes expo-
sure and outcome data sets containing information on SNPs,
alleles, effect sizes (odds ratios [ORs] converted to β statistics by
log transformation), standard errors, P values, and effect allele
frequencies for selected exposure instruments. Herein, we al-
lowedtheforwardstrandofambiguousSNPstobeinferredwhere
possible based on allele frequency information; however, strand-
ambiguous SNPs with intermediate effect allele frequencies
(>0.42) were considered unresolvable. We also conducted sen-
sitivity analyses where strand-ambiguous SNPs were excluded
from MR analysis, which did not change the pattern of findings;
thus, results using the full set of SNPs were reported.
For each direction of potential influence, we combined MR
estimates using inverse variance–weighted (IVW) meta-analysis,
which essentially translates to a weighted regression of SNP-
outcome effects on SNP-exposure effects where the intercept is
constrained to zero. Again, results can be biased if instrument
SNPs show horizontal pleiotropy, influencing the outcome
through causal pathways other than the exposure, thereby vio-
lating instrumental variable assumptions.16 We therefore com-
pared IVW results with other established MR methods whose es-
timatesareknowntoberelativelyrobusttohorizontalpleiotropy,
although at the cost of reduced statistical power.17 These meth-
ods include the weighted median approach, which selects
the median MR estimate as the causal estimate,18 and MR Egger
regression, which allows the intercept to be freely estimated
as an indicator of average pleiotropic bias.16 We also applied
MR-PRESSO(PleiotropyResidualSumandOutlier)19 todetectand
correct for any outliers reflecting likely pleiotropic biases for all
reported results. Effect estimates are reported in β values where
the outcome was continuous (ie, self-reported or objectively as-
sessed physical activity levels) and converted to ORs where the
outcome was dichotomous (ie, MDD status).
To assess robustness of significant results, we conducted fur-
ther tests for horizontal pleiotropy using meta-analytic methods
to detect heterogeneous outcomes, including leave-1-SNP-out
analyses, the modified Cochran Q statistic, and the MR Egger in-
tercept test of deviation from the null.20 These tests vary in their
assumptions but essentially capture the extent to which the ef-
fect for 1 or more instrument SNP is exaggerated in magnitude,
as would be the case if that SNP not only acted through the hy-
pothesizedpathway,butthroughotherunaccountedcausalpath-
ways. Finally, we looked up each instrument SNP and their prox-
ies (r2 > 0.80) in the PhenoScanner GWAS database (version 2;
http://phenoscanner.medschl.cam.ac.uk) to assess any previous
associations (P < 1 × 10−5) with potential confounding traits and
assessed the effects of manually removing these SNPs from the
MR analysis to rule out possible pleiotropic effects.
Results
Accelerometer-Based Physical Activity and Depression
We found evidence of a protective causal relationship between
accelerometer-based physical activity with MDD (IVW OR, 0.74
for MDD per 1-SD unit increase in mean acceleration; 95% CI,
0.59-0.92; P = .006); weighted median and MR Egger analysis
yielded similar pattern of effects (Table 1), with 10 SNPs meet-
ing the relaxed statistical threshold (Figure 2). The MR estimate
was not statistically significant with only 2 genome-wide signifi-
cant SNPs (IVW OR, 1.12; 95% CI, 0.72-1.75; P = .60) (eTable 6 and
eFigure 1 in the Supplement), which provided insufficient data
for alternative MR methods and sensitivity analyses. For the 10
SNPs, MR-PRESSO did not detect any potential outliers. Further-
more, analyses leaving out each SNP revealed that no single SNP
drove these results but rather reflected an overall combined pat-
tern of opposite relationships with physical activity vs MDD
(eFigure 2 in the Supplement). Similarly, the modified Q statis-
tic indicated no notable heterogeneity (Q = 6.01; P = .74) across













B2 indicates the causal relationship of interest to be estimated, where
B2 = B1/B3. B1 and B3 represent estimated direct effects of a genetic variant on
the exposure (eg, physical activity) and outcome (eg, depression), respectively.
Solid paths are theorized to exist; dashed paths are theorized to be
nonsignificant according to MR assumptions.
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instrument SNP effects. The MR Egger intercept test further sug-
gestednohorizontalpleiotropy(intercept,0.008;standarderror,
0.02; P = .60). In the PhenoScanner database, we identified 2 of
the 10 SNPs for accelerometer-based activity nominally associ-
ated with depression-relevant traits (ie, rs59499656 with body
mass index and rs9293503 with educational attainment). How-
ever, removing both SNPs did not change the pattern of results.
When we further mapped SNPs to known genes in public data-
bases and examined whether any genes have been implicated
in GWAS of relevant traits, removing SNPs produced no substan-
tive change in results (eMethods 1, which includes eFigure 3 and
eTables 6 and 7, in the Supplement).
In the other direction, across all MR methods, we found no
evidence of causal relationships of MDD with accelerometer-
based activity (Table 2). MR-PRESSO detected 1 outlier, and
MR estimates remained null after removal of this outlier (IVW
β = −0.08 in mean acceleration per MDD vs control status;
95% CI, −0.47 to 0.32; P = .70). The weighted median and MR
Egger yielded a similar pattern of effects (Table 2 and Figure 3).
Self-reported Physical Activity and Depression
In contrast, we found no statistically significant evidence of a
relationship between self-reported activity and MDD, regard-
less of instrument SNP threshold (outlier-adjusted IVW
OR, 1.28 for MDD per 1-SD increase in metabolic-equivalent
minutes of moderate-to-vigorous activity [95% CI, 0.87-1.90;
P = .21] for 24 top SNPs; IVW OR, 1.45 for MDD per 1-SD increase
in metabolic-equivalent minutes of moderate-to-vigorous ac-
Table 1. MR Results for the Relationship Between Accelerometer-Based Activity Effect and MDD
Method OR (95% CI)a P Value No. of SNPs
IVWb 0.74 (0.59-0.92) .006 10
Weighted medianb 0.71 (0.53-0.95) .02 10
MR Eggerb 0.57 (0.22-1.48) .28 10
Abbreviations: IVW, inverse variance–weighted; MDD, major depressive
disorder; MR, mendelian randomization; OR, odds ratio; SNP, single-nucleotide
polymorphism.
a Indicates odds for MDD per 1-SD increase in mean acceleration.
b No MR-PRESSO (Pleiotropy Residual Sum and Outlier) outliers were detected.
P < 1 × 10−7 for top SNPs.
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rs1550435 –0.06 (–0.15 to 0.03)
rs148193266 –0.07 (–0.15 to 0.01)
rs34517439 –0.07 (–0.16 to 0.02)
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IVW (combined) –0.04 (–0.06 to –0.01)
A, Scatterplot of single-nucleotide polymorphism (SNP) potential effects on
physical activity (PA) vs MDD, with the slope of each line corresponding to
estimated MR effect per method. B, Forest plot of individual and combined SNP
MR-estimated effects sizes. Data are expressed as raw β values with 95% CI.
P < 1 × 10−7 for top SNPs. IVW indicates inverse variance–weighted method.
Table 2. MR Results for the Relationship Between MDD and Accelerometer-Based Activity
Method β (95% CI)a P Value SNPs
Main modelb
IVW −0.08 (−0.47 to 0.32) .70 15
Weighted median −0.07 (−0.62 to 0.48) .82 15
MR Egger −0.13 (−2.11 to 1.86) .90 15
With outlier
IVW 0.05 (−0.41 to 0.51) .83 16
Weighted median −0.04 (−0.59 to 0.51) .98 16
MR Egger 1.05 (−0.96 to 3.06) .33 16
Abbreviations: IVW, inverse
variance–weighted; MDD, major
depressive disorder; MR, mendelian
randomization; OR, odds ratio;
SNP, single-nucleotide
polymorphism.
a Indicates change in mean
acceleration per MDD vs control
status.
b Indicates model with MR-PRESSO
(Pleiotropy Residual Sum and
Outlier) outlier (rs78676209)
removed. P < 1 × 10−6 for top SNPs.
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tivity [95% CI, 0.57-3.37; P = .48] for 6 genome-wide signifi-
cant SNPs) (eTables 9-11 and eFigures 4 and 5 in the Supple-
ment), or between MDD and self-reported activity (for 14 top
SNPs, outlier-adjusted IVW β = 0.02 in standardized metabolic-
equivalent minutes of moderate-to-vigorous activity for MDD
vs control status; 95% CI, −0.008 to 0.05; P = .15) (eTable 12
and eFigure 6 in the Supplement).
Discussion
Depression is a common and debilitating condition, with a high
societal burden of morbidity and mortality.21 As such, identi-
fication of effective strategies for preventing depression has
substantial implications for improving population health. Re-
cent evidence has suggested that physical activity may pro-
tect against the risk for depression.3-5 However, if the relation-
ship between physical activity and depression is not causal,
recommendations to promote physical activity, while benefi-
cial for other health outcomes, would yield limited results for
depression. To strengthen causal inference, we apply a geneti-
cally informed method. Using MR with genetic instruments se-
lected from large-scale GWAS, we find evidence supporting a
potential causal relationship between physical activity and a
reduced risk for depression.
Our results extend current literature in a number of ways.
First, we examined self-reported and objectively measured
(ie, accelerometer-based) physical activity and discovered that
findings on the relationship with depression are specific to ob-
jectively measured—but not self-reported—activity. Meta-
analytic data have shown that self-report and objective mea-
sures can yield discrepant estimates of physical activity.8,22,23
Self-report measures of activity may be affected by mood states
and cognitive biases that also affect mental health, making it
difficult to ascertain whether observed associations are true
or simply artifacts of a common liability. For example, indi-
viduals vulnerable to depression may perceive themselves as
more inactive and disengaged than their peers or compen-
sate by overreporting activity. Although this does not invali-
date the utility of self-reported measures, verifying their con-
clusions with objective measures is essential. Prior work has
indicated that objectively measured physical activity is more
heritable12 and hence may be closer to biological processes that
could directly affect depression, as well as more powerfully in-
strumented by SNPs in the MR context.24 Only 1 prior study,25
to our knowledge, has incorporated genetic information, using
a twin-based design, to assess the relationship between physi-
cal activity and depression. Contrary to our study, it did not
yield evidence of such a relationship, perhaps owing to self-
report measures and restricted definition of physical activity
as leisure exercise (ie, intentionally performed to improve or
maintain fitness) vs physical activity more broadly.2
We estimated a moderate but significant reduction of MDD
risk per 1-SD increase in objectively measured physical activ-
ity. One SD of objectively measured physical activity in the
UK Biobank Study has been reported to be approximately 8
milligravities (or 0.08 m/s2) of acceleration in a mean 5-
second window of analyzed accelerometer data.12,26 Al-
though no straightforward translation of these values into
energy expenditure or step-based metrics is available, an 8-mil-
ligravity increase in mean acceleration is roughly what we
might observe in a 24-hour period if—for example—a person
replaced sedentary behavior with 15 minutes of vigorous ac-
tivity (eg, running); just more than 1 hour of moderate physi-
cal activity (eg, fast walking); or some combination of light ac-
tivity (eg, standing, stretching, easy chores) and more vigorous
activity (eFigure 7 and eTable 13 in the Supplement).
Second, it has remained unclear to date whether inverse
associations between physical activity and depression are ow-
ing potentially to a protective relationship between physical




















0 0.05 0.10 0.15 0.20
MR Effect Size for MDD on PA, β (95% CI)
Forest plotB
–3 –2 –1 0 321
SNP β (95% CI)
rs2060886 1.25 (–0.35 to 2.86)
rs4811079 0.95 (–0.58 to 2.48)
rs1460943 0.64 (–0.87 to 2.16)
rs2451828 0.63 (–0.90 to 2.15)
rs34382743 0.47 (–1.13 to 2.07)
rs6832890 0.29 (–1.20 to 1.78)
rs17499892 0.22 (–1.25 to 1.69)
rs4776768 –0.05 (–1.64 to 1.53)
rs586275 –0.10 (–1.54 to 1.35)
rs1081458 –0.39 (–1.97 to 1.19)
rs1950829 –0.42 (–1.74 to 0.89)
rs12658032 –0.63 (–1.99 to 0.74)
rs1025145 –1.14 (–2.73 to 0.46)
rs1936365 –1.25 (–2.67 to 0.17)
rs7546987 –1.32 (–2.93 to 0.30)
IVW (combined) –0.08 (–0.47 to 0.32)
A, Scatterplot of single-nucleotide polymorphism (SNP) effects on MDD vs their
effects on physical activity (PA), with slope of each line corresponding to
estimated MR effect per method. B, Forest plot of individual and combined SNP
MR-estimated effects sizes. Data are expressed as raw β values with 95% CI.
IVW indicates inverse variance–weighted method.
Assessment of Bidirectional Relationships Between Physical Activity and Depression Among Adults Original Investigation Research
jamapsychiatry.com (Reprinted) JAMA Psychiatry April 2019 Volume 76, Number 4 403
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Vrije Universiteit User  on 12/21/2020
activity and depression and/or a relationship between depres-
sion and reduced physical activity. Using bidirectional MR, we
found evidence of only 1 direction of this relationship, where
physical activity demonstrated a potential causal relation-
ship with depression, while depression does not appear to have
a such a relationship with physical activity. Other factors may
better explain the observed depression-activity relationship7
rather than depression directly compromising physical activ-
ity. For example, underlying conditions such as chronic pain
could interfere with activity and lead to depression. How-
ever, our MR analyses may not be currently powered to de-
tect small effects (for calculations, see eMethods 2 in the
Supplement) that may become apparent when future discov-
ery GWAS are expanded.
Limitations
This study has several limitations. First, although we drew on
the largest available GWAS, some identified few genome-
wide significant SNPs, which could result in relatively weak
genetic instruments. To address this, we applied statistical cri-
teria to include additional SNPs as instruments. This ap-
proach has been used in other MR studies where currently
known genome-wide significant SNPs are limited.14,15 Sec-
ond, despite selecting strongly associated SNPs, common SNPs
do not yet explain much total variance in complex traits27 and
so cannot be considered exact proxies of the exposure. In ad-
dition, because we do not yet know the biological action of
these SNPs, it is impossible to fully rule out pleiotropic mecha-
nisms without detailed functional follow-up of these loci,
although we conducted the most up-to-date array of sensitiv-
ity analyses to rule out horizontal pleiotropy. Although hori-
zontal pleiotropy is a concern for MR inference, vertical plei-
otropy—in which an exposure acts on an outcome via other
variables along the same causal pathway—is acceptable.17 For
example, if physical activity causally reduces body mass in-
dex, and then body mass index causally affects MDD, this rep-
resents vertical pleiotropy for which we should not unneces-
sarily penalize the MR estimate.24 However, it is reassuring that
our observed MR estimate was robust across sensitivity analy-
ses, suggesting negligible bias from evident sources of pleiot-
ropy. Third, we used summary GWAS data for MDD and not
for depressive symptoms in individuals with or without MDD.
Although meta-analyses have shown that physical activity is
associated with improved symptoms in individuals with
depression,9,10,28 our study was not designed to address this
issue. Also, we only considered overall levels of physical ac-
tivity in relation to depression, whereas recent work has
revealed complicated associations between the type, dura-
tion, frequency, and intensity of physical activity and mental
health29 that could affect the size and direction of observed
MR estimates but could not be assessed in the present study.
Fourth, SNPs associated with physical activity were identi-
fied in the UK Biobank Study, which consists of individuals
aged 40 to 70 years, whereas samples in the MDD GWAS in-
cluded a wider range of age groups. Physical activity in younger
individuals may be influenced by other variants that share
different associations with MDD, although such GWAS data a
re not yet available. Moreover, we do not have demographic
data on all of the GWAS participants, such as age and sex, which
limits clinical generalizability of these findings to other popu-
lations. Finally, we cannot interpret effect sizes in the same
way as a clinical trial in which individuals are assigned to a
discrete program of physical activity of defined length, be-
cause MR estimates reflect lifelong effects of assignment to
genetic variants. However, our MR estimate is notably similar
in magnitude to those of recent meta-analytic observational
data.5
Despite these limitations, our application of MR repre-
sents a test of whether genetic instruments provide indepen-
dent support for potentially protective relationships be-
tween physical activity and depression risk. Our novel
triangulation of genetic variants as instruments for causal
inference30 obviates typical challenges for observational re-
search while strengthening evidence from such studies.3-5
Stronger evidence of causal relationships is of great impor-
tance because few modifiable factors for preventing depres-
sion are known. If physical activity truly reduces risk for de-
pression, it would be useful to promote physical activity not
only in the population at large, where this can yield public
health returns at the level of human productivity and re-
duced health care burden, but also for individuals at risk for
developing new depression, such as adolescents or those fac-
ing depressogenic exposures, such as violence-exposed indi-
viduals or workers in high-stress environments.
Conclusions
This study leverages MR to support causal inference regard-
ing putative protective factors in mental health. Our findings
validate a potential protective relationship between physical
activity and depression and point to the importance of objec-
tive measurement of physical activity in epidemiologic stud-
ies of mental health. Overall, this study supports the hypoth-
esis that enhancing physical activity is an effective prevention
strategy for depression.
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